Therapeutic plasmapheresis and more specific methods of extracorporeal LDL-cholestrol elimination;Terapeutická plazmaferéza a specifičtějš t́ metody extrakorporální eliminace cholesterolu

Aktuality v Nefrologii

Volumn 15, Issue 4, 2009, Pages 154-158

  Bláha, Milan ^a   Blažek, Martin ^a   Bláha, Vladimír ^b   Cermanová, Melanie ^a   Filip, Stanislav ^c   Andrýs, Ctirad ^d   Lánská, Miriam ^b   Malý, Jaroslav ^b  

^a II Interní Klinika LF UK V Hradci Králové   (United Kingdom)

^b Geronto metabolická Klinika LF UK V Hradci Králové   (United Kingdom)

^c Onkologická a Radioterapeutická Klinika LF UK V Hradci Králové   (United Kingdom)

^d Ústav Imunologie a Alergologie LF UK V Hradci Králové ^*  (United Kingdom)

Author keywords

Extracorporeal elimination; Familial hyperlipoproteinemia; Hemorheopheresis; LDL apheresis; Therapeutic hemapheresis

Indexed keywords

APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR; CELL ADHESION MOLECULE; ENDOGLIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROMATOSIS; ATHEROSCLEROSIS; CHILD; CLINICAL ARTICLE; COMPUTER PROGRAM; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PLASMA VOLUME; PLASMAPHERESIS; PRESCHOOL CHILD; SCHOOL CHILD;

EID: 75149187046     PISSN: 1210955X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bláha M, Andrýs A, Bláha V, Krejsek J, Skořepová M, Filip S, Malý J, Blažek M. Adhesive selectin molecules during extracorporeal cholesterol elimination. The Hematology Journal 2003;4, Suppl. 2:23-24. ISSN 1466-4860.
2. Bláha M, Cermanová M, Bláha V, Blažek M, Malý J, Široký O, Solichová D, Filip S, Řeháček V. Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. Ther Apher Dial 2007;11:9-15.
3. Bláha M, Cermanová M, Bláha V, Jarolím P, Andrýs C, Blažek M, Malý J, Smolej L, Zajíc J, Mašin V, Zimová R, Řeháček V. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis 2008;197:264-270.
4. Bláha M, Mašín V, Stránský P, Bláha V, Cermanová M, Malý J, Belada D. Optimization of the therapeutic procedure during LDL-apheresis - a computerized model. Transf Sci 2005;32:149-156.
5. Blaha M, Pecka M, Urbankova J, Blaha V, Maly J, Zadak Z, Blažek M. Activity of Thrombocytes as a Marker of Sufficient Intensity of LDL-apheresis in Familial Hypercholesterolaemia. Transfus Apher Sci 2004;30:83-87.
6. Blaha M, Strasova A, Ungerman L, Blazek M, Blaha V, Maly J, Masin V. Significance of Non-Invasive Cardiovascular Examinations for the Evaluation of extracorporeal LDL-Cholesterol Elimination Efficacy. Abstract. Transfusion Medicine and Hemotherapy 2008;35. Suppl. 1:80. ISSN 1660-3796.
7. Blažek M, Bláha M, Malý J, Pecka M, Bláha V, Mǎsín V. Changes of metabolic and hemostatic parameters in familial hypercholesterolemia after LDL-apheresis. (In Czech.) Hradec Králové (CZ): Nucleus 2007.
8. Borberg H. Quo vadis, haemapheresis. Current developments in haemapheresis. Transf Apher Sci 2006;34:51-73.
9. Borberg H. 28Years of LDL-Apheresis: a Rewiev of Experience. Transfus Apher Sci 2009; Jun 24. [Epub ahead of print]
10. DeGennes JL, Maunand B. Formes homozygotes cutaneo-tendineuses de xanthomatose hypercholesterolemique dans dans une observation familiale exemplaire-essai de plasmapherese a titre du traitement heroique. Bulletins er Memoires de la Societe Médicale des Hospitaux de Paris 1967;118:1377-87.
11. Karasek D, Vaverkova H, Halenka M, Budikova M, Novotny D. Brachial endothelial function in subjects with familial combined hyperlipidemia and its relationship to a carotid artery intima media thickness. International Angiology 2006;25:418-426.
12. Lorenz MW, von Keller S, Steinmetz H, Markus HS, Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range. Stroke 2006;37:87-92.
13. Lupien PJ, Moorjani S, Awad J. A new approach to the management of familial hypercholesterolaemia: Removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet 1976;1(7972):1261-5.
14. Pták J. Immunoadsorption in the therapy of myasthenia gravis. (In Czech.) Praha; Galén, 2004:1-128.
15. Stoffel W, Borberg H, Grepe V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet 1981;318:1005-1007.
16. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL. The new approach to assignment of ASFA categories-introduction to the fourth special issue: clinical applications of therapeutic apheresis J Clin Apher. 2007 Jun;22(3):96-105. Review.
17. Šmánek M, Urbanová Z.: Cholesterol and triglyceride levels and their development. Čas Lék. Čes 1997;136:380-5.
18. Tompson GR. LDL apheresis. Atherosclerosis 2003; 167: 221-225.
19. Thomspon GR, HEART-UK LDL-Apheresis Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198:247-255.
20. Thompson GR, Lowenthal R, Mayant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975;1(7918):1208-11.
21. Thompsen J, Thompson PD. A systematic review of LDL-apheresis in the treatment of cardiovascular diseases. Atherosclerosis 2006,189: 31-38.
22. Williams RR, Hunt SC. Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171-6.